Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zyversa Therapeutics Inc (ZVSA)

Zyversa Therapeutics Inc (ZVSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,649
  • Shares Outstanding, K 2,344
  • Annual Sales, $ 0 K
  • Annual Income, $ -98,300 K
  • EBIT $ -22 M
  • EBITDA $ -10 M
  • 60-Month Beta 0.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -6.30
  • Number of Estimates 1
  • High Estimate -6.30
  • Low Estimate -6.30
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0401 +6.80%
on 11/15/24
3.3700 -67.04%
on 11/05/24
-0.9892 (-47.10%)
since 10/25/24
3-Month
1.0401 +6.80%
on 11/15/24
3.3700 -67.04%
on 11/05/24
-1.8492 (-62.47%)
since 08/23/24
52-Week
1.0401 +6.80%
on 11/15/24
42.3850 -97.38%
on 11/30/23
-27.7292 (-96.15%)
since 11/24/23

Most Recent Stories

More News
ZyVersa Therapeutics Announces Promising Findings for Inflammasome ASC Inhibitor IC 100 in Stroke-Related Cardiovascular Injury

ZyVersa announces data showing Inflammasome ASC Inhibitor IC 100 may improve cardiac function post-stroke related to obesity.Quiver AI SummaryZyVersa Therapeutics has announced promising new data regarding...

ZVSA : 1.1150 (-1.33%)
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

ZVSA : 1.1150 (-1.33%)
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

ZVSA : 1.1150 (-1.33%)
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

ZVSA : 1.1150 (-1.33%)
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

ZVSA : 1.1150 (-1.33%)
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

ZVSA : 1.1150 (-1.33%)
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

ZVSA : 1.1150 (-1.33%)
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

ZVSA : 1.1150 (-1.33%)
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

ZVSA : 1.1150 (-1.33%)
ZyVersa Therapeutics Appoints Three New Board Members

/PRNewswire/ -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa"), a clinical- stage specialty biopharmaceutical company developing first-in-class drugs...

ZVSA : 1.1150 (-1.33%)
FWBI : 2.96 (+4.59%)

Business Summary

ZyVersa Therapeutics Inc. is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates which address high unmet medical needs in the areas of renal and inflammatory diseases. The company's development pipeline includes phase 2a ready...

See More

Key Turning Points

3rd Resistance Point 1.2275
2nd Resistance Point 1.1800
1st Resistance Point 1.1550
Last Price 1.1150
1st Support Level 1.0825
2nd Support Level 1.0350
3rd Support Level 1.0100

See More

52-Week High 42.3850
Fibonacci 61.8% 26.5912
Fibonacci 50% 21.7126
Fibonacci 38.2% 16.8339
Last Price 1.1150
52-Week Low 1.0401

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar